PAM
NPCE icon

Panagora Asset Management’s Neuropace NPCE Stock Holding History

Panagora Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
114,275
+56,267
+97% +$844K 0.01% 635
2025
Q4 		$896K Sell
58,008
-1,687
-3% -$22.6K ﹤0.01% 749
2025
Q3 		$615K Sell
59,695
-40,094
-40% -$378K ﹤0.01% 758
2025
Q2 		$1.11M Buy
+99,789
New +$1.25M 0.01% 605

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Panagora Asset Management's NPCE Position: Q1 2026 in Review

Panagora Asset Management increased its Neuropace (NPCE) stake by 97% in Q1 2026, buying an estimated $844K and bringing the position to 114,275 shares worth $1.5M. The position accounts for 0.01% of the portfolio, ranked #635.

Panagora Asset Management first reported a position in NPCE in Q2 2025 and has held it in 4 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Panagora Asset Management held 114,275 shares of Neuropace worth $1.5M as of Q1 2026.
  • Panagora Asset Management bought 56,267 Neuropace shares in Q1 2026, an estimated $844K.
  • Neuropace made up 0.01% of Panagora Asset Management's portfolio in Q1 2026, its #635 holding.
  • Panagora Asset Management first reported a position in Neuropace in Q2 2025 and has held it in 4 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.